Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Maravai LifeSciences Holdings's Revenue for the
three
months ended in Mar. 2026 was $65.8 Mil. Maravai LifeSciences Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was $29.5 Mil.
Hence, Maravai LifeSciences Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.24.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Maravai LifeSciences Holdings Receivables Turnover Related Terms
Maravai LifeSciences Holdings Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRVI vs LBRX, SLDB, JANX: Receivables Turnover Comparison
For the Biotechnology subindustry, Maravai LifeSciences Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maravai LifeSciences Holdings (MRVI) has a Receivables Turnover of 2.24 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Maravai LifeSciences Holdings and its competitors. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #277 out of 841 companies in the Biotechnology industry, placing it in the top 32.9%.
Is Maravai LifeSciences Holdings' Receivables Turnover too high?
Maravai LifeSciences Holdings' current Receivables Turnover is 2.24. The Biotechnology industry median Receivables Turnover is 5.29. Maravai LifeSciences Holdings' value of 2.24 is 57.7% below this industry median. Based on the distribution chart, Maravai LifeSciences Holdings ranks #277 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Maravai LifeSciences Holdings has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' Receivables Turnover compare to LBRX and SLDB?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #277 out of 841 companies for Receivables Turnover. This puts Maravai LifeSciences Holdings in the upper half of its industry. The industry median Receivables Turnover is 5.29. Maravai LifeSciences Holdings' value of 2.24 is 57.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maravai LifeSciences Holdings's current Receivables Turnover of 2.24 is 57.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Maravai LifeSciences Holdings and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maravai LifeSciences Holdings's current Receivables Turnover is 2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings (MRVI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.82, compared to a current price of $7.24 — trading 89.5% above its estimated fair value. The current Receivables Turnover is 2.24 and 57.7% below the Biotechnology industry median of 5.29. Maravai LifeSciences Holdings' overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MRVI), the current Receivables Turnover is 2.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of $7.24 is trading 89.5% above its estimated GF Value™ of $3.82.
GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.
Key valuation signals for MRVI:
Receivables Turnover: 2.24
GF Value™: $3.82 vs. price of $7.24 (89.5% above fair value)
Industry Position: 57.7% below the Biotechnology median (#277 of 841)
No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Business Description
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
56GF Score
Get the complete analysis for MRVI
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRVI has been successfully added to your 
